Literature DB >> 10493674

Drug associated cutaneous vasculitis in adults in northwestern Spain.

C García-Porrúa1, M A González-Gay, L López-Lázaro.   

Abstract

OBJECTIVE: To examine the incidence and clinical features of adults with biopsy proven cutaneous vasculitis (CV) associated with drugs.
METHODS: Retrospective study of an unselected population of adults (age >20 years) with biopsy proven leukocytoclastic CV from 1988 through 1997. Drug associated CV was considered if CV was confirmed by a skin biopsy and there was a history of drug use within one week before the development of CV. Drug associated CV was classified by American College of Rheumatology (ACR) criteria. To differentiate Henoch-Schonlein purpura (HSP) from hypersensitivity vasculitis (HV), the traditional criteria proposed by Michel, et al were used (J. Rheumatol. 1992;19:721-8).
RESULTS: Thirty-three of 138 patients (23.9%) presenting with biopsy proven CV were diagnosed with drug associated CV. The annual incidence rate of biopsy proven drug associated CV in adults was 17.49 cases/million (95% CI 11.53-23.46): men 25.10/million (95% CI 14.85-35.36), women 10.31/million (95% CI 3.92-16.70). Antibiotics (n = 13), especially amoxicillin, and analgesics or nonsteroidal anti-inflammatory drugs (n = 11) were the drugs more commonly associated with CV. All adults with drug associated CV met the ACR classification criteria for HV or HSP. Based on Michel's criteria 26 patients (78.8%) were classified as having HV and 7 HSP. No patient met ACR criteria for other systemic vasculitides. Complete recovery with no sequelae was observed in most cases.
CONCLUSION: Among patients with CV, drug associated disease is common and usually has a good clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493674

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota.

Authors:  Amrita Arora; David A Wetter; Tania M Gonzalez-Santiago; Mark D P Davis; Christine M Lohse
Journal:  Mayo Clin Proc       Date:  2014-06-27       Impact factor: 7.616

2.  Incidence of autoimmune diseases in patients with scabies: a nationwide population-based study in Taiwan.

Authors:  Jui-Ming Liu; Feng-Hsiang Chiu; Chien-Yu Lin; Fung-Wei Chang; Ren-Jun Hsu
Journal:  Rheumatol Int       Date:  2017-04-18       Impact factor: 2.631

3.  Severe leukocytoclastic vasculitis secondary to the use of a naproxen and requiring amputation: a case report.

Authors:  Keri Brown; Jeanine Martin; Susan Zito
Journal:  J Med Case Rep       Date:  2010-07-01

Review 4.  Ceftriaxone-induced leukocytoclastic vasculitis: a case report and literature review of antibiotic-induced leukocytoclastic vasculitis.

Authors:  Aseel A Almasoudi; Eman S Bablghaith; Samaher I Alaauldeen; Ayman M Falemban; Ahlam A Sherbeeni; Adeeb A Bulkhi
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

Review 5.  Diagnosis and management of leukocytoclastic vasculitis.

Authors:  Paolo Fraticelli; Devis Benfaremo; Armando Gabrielli
Journal:  Intern Emerg Med       Date:  2021-03-13       Impact factor: 3.397

Review 6.  Cutaneous vasculitis: a rheumatologist perspective.

Authors:  Trinitario Pina; Ricardo Blanco; Miguel A González-Gay
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.919

7.  Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure.

Authors:  Sachin R Agrawal; Atul Rajput; A P Jain
Journal:  J Pharmacol Pharmacother       Date:  2014-10

Review 8.  Overview of infections as an etiologic factor and complication in patients with vasculitides.

Authors:  Panagiotis Theofilis; Aikaterini Vordoni; Maria Koukoulaki; Georgios Vlachopanos; Rigas G Kalaitzidis
Journal:  Rheumatol Int       Date:  2022-02-14       Impact factor: 3.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.